Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab
Status:
Recruiting
Trial end date:
2024-10-31
Target enrollment:
Participant gender:
Summary
Pyrotinib is an oral tyrosine kinase inhibitor targeting both HER-1 and HER-2 receptors. This
study is a randomized, open-label, multi-center, parallel design study of the combination of
pyrotinib, trastuzumab and chemotherapy versus trastuzumab and chemotherapy in HER2+ MBC
patients, who have prior received trastuzumab and pyrotinib. Patients will be randomized in a
2:1 ratio to one of the following treatment arms. Arm A: pyrotinib + trastuzumab +
chemotherapy, Arm B: trastuzumab + chemotherapy. Patients will receive either arm of therapy
until disease progression, unacceptable toxicity, or withdrawal of consent.